
What is claimed is:

1. A compound of Formula I:



Formula I

wherein

each of R^1 and R^2 individually is H, C_{1-6} alkyl, or aryl-substituted C_{1-6} alkyl, or R^1 and R^2 combine with the nitrogen atom to which they are attached to form a 3- to 8-membered ring, which ring may be optionally substituted with C_{1-6} alkyl, aryl, C_{1-6} alkoxy, or aryloxy substituents;

R^3 is H, C_{1-6} alkyl, or C_{1-6} alkoxy-substituted C_{1-6} alkyl;

each of R^4, R^5, R^6, and R^7 individually is H, C_{1-6} alkyl, or C_{1-6} alkoxy;

L^1 is a linker species selected from the group consisting of CR^8R^9, $CR^8R^9CR^{10}R^{11}$, and O;

L^2 is a linker species selected from the group consisting of CH_2, CH_2CH_2, $CH_2CH_2CH_2$, and $CH_2CH_2CH_2CH_2$;

each of R^8, R^9, R^{10}, and R^{11} individually is hydrogen or C_{1-6} alkyl; and

the dashed line indicates an optional double bond;

or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1, wherein R^1 is H and R^2 is C_{1-6} alkyl.

3. The compound of claims 1 or 2, wherein R^3 is C_{1-6} alkyl.

4. The compound of any one of claims 1 – 3, wherein each of R^4, R^5, R^6, and R^7 is H.

5. The compound of any one of claims 1 – 4, wherein L^1 is CR^8R^9, and each of R^8 and R^9 is hydrogen.

6. The compound of any one of claims 1 – 5, wherein L^2 is CH_2CH_2.

7. The compound of any one of claims 1 – 6, wherein the dashed line is a single bond.

8. A pharmaceutical composition comprising a compound as claimed in any one of claims 1 – 7 and a pharmaceutically acceptable carrier.

9. A method for the treatment or prevention of a disease or condition mediated by a neuronal nicotinic receptor comprising the administration of a compound as claimed in any one of claims 1 – 7.

10. The method of claim 9, wherein the disease or condition is IBS-D, OAB, nicotine addiction, smoking cessation, depression, major depressive disorder, or hypertension.

11. Use of a compound as claimed in any one of claims 1 – 7, for the preparation of a medicament for the treatment or prevention of a disease or condition mediated by a neuronal nicotinic receptor.

12. The use of claim 11, wherein the disease or condition is IBS-D, OAB, nicotine addiction, smoking cessation, depression, major depressive disorder, or hypertension..


13. A compound as claimed in any one of claims 1 – 7, for use as an active therapeutic substance.

14. A compound as claimed in any one of claims 1 – 7, for use in the treatment or prevention of a disease or condition mediated by a neuronal nicotinic receptor.

15. The compound of claim 13 or 14, wherein the disease or condition is IBS-D, OAB, nicotine addiction, smoking cessation, depression, major depressive disorder, or hypertension.

What is claimed is:

1. A compound of Formula I:



Formula I

wherein

each of R^1 and R^2 individually is H, C_{1-6} alkyl, or aryl-substituted C_{1-6} alkyl, or R^1 and R^2 combine with the nitrogen atom to which they are attached to form a 3- to 8-membered ring, which ring may be optionally substituted with C_{1-6} alkyl, aryl, C_{1-6} alkoxy, or aryloxy substituents;

R^3 is H, C_{1-6} alkyl, or C_{1-6} alkoxy-substituted C_{1-6} alkyl;

each of R^4, R^5, R^6, and R^7 individually is H, C_{1-6} alkyl, or C_{1-6} alkoxy;

L^1 is a linker species selected from the group consisting of CR^8R^9, $CR^8R^9CR^{10}R^{11}$, and O;

L^2 is a linker species selected from the group consisting of CH_2, CH_2CH_2, $CH_2CH_2CH_2$, and $CH_2CH_2CH_2CH_2$;

each of R^8, R^9, R^{10}, and R^{11} individually is hydrogen or C_{1-6} alkyl; and

the dashed line indicates an optional double bond;

or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1, wherein R^1 is H and R^2 is C_{1-6} alkyl.

3. The compound of claims 1 or 2, wherein R^3 is C_{1-6} alkyl.

4. The compound of any one of claims 1 – 3, wherein each of R^4, R^5, R^6, and R^7 is H.

5. The compound of any one of claims 1 – 4, wherein L^1 is CR^8R^9, and each of R^8 and R^9 is hydrogen.

6. The compound of any one of claims 1 – 5, wherein L^2 is CH_2CH_2.

7. The compound of any one of claims 1 – 6, wherein the dashed line is a single bond.

8. A pharmaceutical composition comprising a compound as claimed in any one of claims 1 – 7 and a pharmaceutically acceptable carrier.

9. Use of a compound as claimed in any one of claims 1 – 7, for the preparation of a medicament for the treatment or prevention of IBS-D, OAB, nicotine addiction, smoking cessation, depression, major depressive disorder, or hypertension.

10. The compound as claimed in any one of claims 1 – 7, for use as an active therapeutic substance.

11. The compound as claimed in any one of claims 1 – 7, for use in the treatment or prevention of a disease or condition mediated by a neuronal nicotinic receptor.

12. The compound of claim 10 or 11, wherein the disease or condition is IBS-D, OAB, nicotine addiction, smoking cessation, depression, major depressive disorder, or hypertension.